Sunday 11 October 2026 Export all EQ data to Excel Powerpack

Equillium, Inc.

EQ Healthcare Biotechnology

Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.

1.41 0.03 −2.08%
Market cap
$91.3M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
−6.75
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(58.98%) (54.39%) (93.99%) (90.24%)

+8 more TTM periods

ROA
(50.68%) (47.75%) (77.92%) (70.81%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(32.34%) (32.22%) (79.23%) (79.64%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.18) (0.20) (0.40) (0.35)
Free Cash Flow
(20.08) (18.91) (22.78) (22.92)
Capital Expenditures
(0.11) (0.03) (0.04) (0.01)
Other line items
Cash ROIC
(17.74%) (15.66%) (38.70%) (35.78%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Operating CF/Net income
1.11 0.99 1.02 0.94
Depreciation/Fixed assets
0.54 0.50 0.62 0.26
Capex/Depreciation
(1.05) (0.33) (0.35) (0.18)
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.18) (0.20) (0.40) (0.35)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates